Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody

Theranostics

Volumn 4, Issue 7, 2014, Pages 708-720

  D'Huyvetter, Matthias ^a   Vincke, Cécile ^a   Xavier, Catarina ^a   Aerts, An ^a   Impens, Nathalie ^a   Baatout, Sarah ^a   De Raeve, Hendrik ^a   Muyldermans, Serge ^a   Caveliers, Vicky ^a   Devoogdt, Nick ^a   Lahoutte, Tony ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

177 Lutetium.; HER2; nanobody; targeted radionuclide therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LUTETIUM; MONOCLONAL ANTIBODY; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB;

ANIMAL; FEMALE; HUMAN; IMMUNOLOGY; MALE; MOUSE; NUDE MOUSE; OVARIAN NEOPLASMS; PROCEDURES; RADIOIMMUNOTHERAPY; RAT; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; FEMALE; HUMANS; LUTETIUM; MALE; MICE; MICE, NUDE; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; RECEPTOR, ERBB-2; SINGLE-CHAIN ANTIBODIES;

EID: 84904546771     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8156     Document Type: Article

References (0)